A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
Taiho Oncology, Inc.
Eli Lilly and Company
Eli Lilly and Company
CanBas Co. Ltd.
Bayer
Critical Outcome Technologies Inc.
Amgen